Why compliance is becoming a competitive edge in pet supplements

Compliance is being reframed as a growth strategy in the pet supplement and treat market. In a PetfoodIndustry article published April 16, 2026, Asa Waldstein of Apex Compliance said the companies gaining ground are the ones embedding compliance early, before products hit shelves or online marketplaces. His argument is straightforward: ingredient review, supplier qualification, manufacturing oversight, and disciplined claims review can reduce regulatory risk while also making a brand more attractive to retailers, investors, and acquisition partners. (petfoodindustry.com)

That message arrives at a moment when the regulatory picture is getting more complicated, not less. FDA says animal food products must meet federal labeling requirements and are also subject to individual state laws, while many states rely on AAFCO model regulations in shaping their own rules. FDA also draws a hard line on claims: if a label or related promotional material says or implies a product will cure, treat, prevent, or mitigate disease, that can signal intended use as a new animal drug. (fda.gov)

At the same time, the broader labeling environment is shifting. AAFCO’s Pet Food Label Modernization project, launched in 2015, is the first major overhaul of model pet food labeling rules in decades, with a goal of making labels more transparent and more familiar to consumers. While that initiative is centered on pet food and specialty pet food, it adds to the compliance burden for companies operating across foods, treats, and supplement-adjacent products, especially those trying to align packaging, substantiation, and state registrations across multiple channels. (aafco.org)

Waldstein’s specific warning is that marketing is often where companies stumble. In the PetfoodIndustry report, he said many businesses ultimately get into trouble because of their marketing, particularly digital claims that outpace the underlying regulatory support. He also pointed to contamination and formulation risks, noting that product development decisions matter just as much as label copy. The article cites examples such as xylitol, high doses of vitamin D3, and alpha lipoic acid as ingredients that may be familiar in human supplements but can pose safety concerns in animals. (petfoodindustry.com)

Other industry voices are describing the same pressure from a different angle. In a May 7, 2026, PetfoodIndustry analysis, Venable partner Todd Harrison said supplement and treat manufacturers are working through a fragmented system in which federal expectations, state requirements, and industry practices often collide. He described labeling as a particular pain point, with companies trying to satisfy more consumer-friendly disclosure expectations while also fitting into state frameworks rooted in feed regulation. Harrison said many manufacturers now use National Animal Supplement Council standards as a practical baseline for compliance and post-market surveillance. (petfoodindustry.com)

That helps explain why third-party frameworks are gaining visibility. In April 2026, NASC said it had expanded its Quality Seal program to include pet treats, its first major scope expansion in 25 years. The group said the move was meant to address regulatory confusion in the treat category and create a more consistent compliance pathway. For companies selling into veterinary, specialty retail, and e-commerce channels at once, those kinds of signals may increasingly function as shorthand for process maturity. (petfoodindustry.com)

Why it matters: For veterinary professionals, the takeaway is practical. As supplements and functional treats keep proliferating, compliance posture can be a useful proxy for how seriously a company takes formulation controls, adverse event monitoring, label discipline, and evidence standards. It doesn't replace clinical judgment or product-by-product review, but it can help clinics assess which brands are less likely to create confusion for staff or pet parents through unsupported claims or inconsistent quality systems. In a market where FDA oversight, state enforcement, and category definitions remain uneven, compliance is increasingly tied to trust. (fda.gov)

What to watch: The next phase will likely center on three fronts: FDA’s enforcement posture on intended-use claims, continued rollout of AAFCO-driven labeling changes across the broader pet product ecosystem, and whether industry pressure produces a clearer federal framework for animal health supplements. Until then, companies that build review systems early, and can document them, may keep turning compliance into a commercial advantage. (fda.gov)